In two randomized phase‑3 trials, a single‑pill triple low‑dose antihypertensive combination achieved blood pressure reductions comparable to amlodipine and superior to losartan monotherapy over 8 weeks.

Sdamlo’s FDA approval offers a new oral solution option for delivering amlodipine, addressing administration challenges in patients who cannot tolerate tablets.

Baxdrostat significantly reduced seated systolic blood pressure compared to placebo in 796 patients, with placebo-adjusted reductions of 9.8 mmHg and 8.7 mmHg at the 2 mg and 1 mg doses respectively, without impacting cortisol levels.

Maine enacted LD 2088 on April 6, 2026, becoming the first state to achieve all three AAPA modernization priorities: optimal PA practice, PA Licensure Compact adoption, and the physician associate title change.

Researchers are increasingly studying peripheral biomarkers in high-risk populations to improve diagnosis and prediction, with standard therapies currently limited to temporary symptom relief.

A recent vehicle recall highlights a rare but potentially fatal pediatric injury risk associated with powered car seats, where rapid thoracic compression may occur with few external warning signs.